Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
Age
35 - 70 years
Sex
ALL
Healthy Volunteers
No
Va San Diego Healthcare System
San Diego, California, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Temple University General Clinical Research Center
Philadelphia, Pennsylvania, United States
Start Date
April 1, 2009
Primary Completion Date
August 1, 2010
Completion Date
August 1, 2010
Last Updated
April 24, 2017
116
ACTUAL participants
Dapagliflozin
DRUG
Placebo
DRUG
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04943861